Abstract 395P
Background
Many pts with ER+ BC experience disease relapse during/after adjuvant endocrine therapy (ET) or develop resistance due to ESR1 mutations. G is a highly potent non-steroidal oral (PO) selective ER antagonist and degrader; IPAT is a potent, PO, AKT inhibitor. We present a 16-week IA of G vs. G + IPAT in MORPHEUS BC (NCT04802759).
Methods
Pts with disease progression on 1–2 lines of ET (including a cyclin-dependent kinase 4/6 inhibitor [CDK4/6i]) for LA/mBC were randomised 1:6 to G (30 mg PO daily [QD]) or G + IPAT (400 mg PO QD; Days 1–21 per 28-day cycle) until disease progression/unacceptable toxicity. Primary endpoints were safety and objective response rate (ORR); other endpoints included progression-free survival, overall survival, clinical benefit rate (CBR), disease control rate, duration of response and pharmacokinetics. Genetic alterations were defined using baseline circulating tumour DNA.
Results
As of 17 May 2022, eight and 24 pts (23 evaluable) were enrolled in the G and G + IPAT arms, respectively; 50% (n = 4)/75% (n = 18) received one prior line and 38% (n = 3)/25% (n = 6) received two prior tx lines for LA/mBC. In the overall population the ORR was 0%/17% (n = 4) and stable disease (SD) was 63% (n = 5)/52% (n = 12) in the G and G + IPAT arms, respectively. In pts with AKT signalling alterations (G = 3; G + IPAT = 10), ORR was 0%/30% (n = 3) and SD was 67% (n = 2)/70% (n = 7). Updated data will be presented including longer follow-up and CBR. Table: 395P
Safety data are % of pts | G | G + IPAT |
Tx-related adverse events (TRAEs) Grade 3–4 | 63% 0 | 96% 35% |
AE/TRAE leading to tx discontinuation | 0 | 9% |
AEs leading to dose modification/interruption | 13% | 52% |
Fatal AEs | 0 | 0 |
Most common TRAEs (≥ 20% incidence rate) | Fatigue; insomnia | Diarrhoea; nausea; constipation; rash; vomiting |
Conclusions
Encouraging activity was seen with G + IPAT in pts with disease progression on 1–2 lines of ET (including a CDK4/6i), especially in pts with AKT signalling alterations. G + IPAT was well tolerated, with no unexpected safety signals.
Clinical trial identification
NCT04802759; 17 March 2021.
Editorial acknowledgement
Research support for third-party writing assistance for this abstract, furnished by Chantel Swart, Ph.D. of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
K.H. Jung: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Advisory Role: AstraZeneca, Celgene, Eisai, F. Hoffmann-La Roche Ltd, Takeda Bixink, Everest Medicine, Daiichi Sankyo, Pfizer, MSD, Novartis . S.J. Luen: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer. M. Oliveira: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Advisory Role: AstraZeneca, Daiichi Sankyo/AstraZeneca, Gilead Sciences, ITeos Therapeutics, Pierre Fabre, F. Hoffmann-La Roche Ltd/Genentech, Inc., Seagen; Financial Interests, Personal, Other, Honoraria: Eisai Europe, Guardant Health, MSD, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, Seagen; Financial Interests, Institutional, Research Funding: AstraZeneca, Boehringer Ingelheim, GSK, Immunomedics, Novartis, Puma Biotechnology, F. Hoffmann-La Roche Ltd/Genentech, Inc., Seagen, Zenith Epigenetics; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Eisai, Novartis, Pierre Fabre, F. Hoffmann-La Roche Ltd. J. Sohn: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd; Financial Interests, Institutional, Research Funding: AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, GSK, Lilly, MSD, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, Sanofi. S. Im: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GSK, Hanmi, Lilly, MSD, Novartis, Pfizer, F. Hoffmann-La Roche Ltd/Genentech, Inc.; Financial Interests, Institutional, Research Funding: AstraZeneca, Daewoong Pharmaceutical, Eisai, Pfizer, F. Hoffmann-La Roche Ltd/Genentech, Inc.. S. Wander: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Advisory Role: Biovica, Eli Lilly, Foundation Medicine Inc., Hologic, Pfizer, Puma Biotechnology, Vercyte ; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly, Guardant Health, 2ndMD; Financial Interests, Institutional, Research Funding: Genentech, Inc., Eli Lilly, Nuvation Bio, Pfizer, Regor Therapeutics. S.A. Hurvitz: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks/Shares: Ideal Implant (I), ROM Tech (I); Financial Interests, Institutional, Research Funding: Ambrx, Amgen, Arvinas, Bayer, Biomarin, Cascadian Therapeutics, Daiichi Sankyo, Dignitana, Genentech, Inc./F. Hoffmann-La Roche Ltd, Gilead Sciences, GSK, Immunomedics, Lilly, Macrogenics, Merrimack, Novartis, OBI Pharma, Pfizer, Phoenix Mole; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Lilly. A. Sonnenblick: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Advisory Role: AstraZeneca, Eli Lilly, F. Hoffmann-La Roche Ltd, Gilead, MSD, Novartis, Pfizer, Progenetics; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly, F. Hoffmann-La Roche Ltd, Novartis, Pfizer, Teva; Financial Interests, Institutional, Research Funding: F. Hoffmann-La Roche Ltd, Novartis; Financial Interests, Personal, Other, Travel, accommodations, expenses: Celgene, F. Hoffmann-La Roche Ltd, Medison, MSD, Neopharm. V. Breton: Non-Financial Interests, Institutional, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd. A. Collier: Other, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Full or part-time Employment: Genentech, Inc.. S. Deb, H. Ngo, R. Schwab, C. Shemesh : Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Full or part-time Employment: Genentech, Inc.. J. Zhu: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd Genentech, Inc.; Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd Genentech, Inc.. C. Hernando Melia: Non-Financial Interests, Personal, Other, Research funding: Support for third-party writing assistance from F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
358P - Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Presenter: Savannah Roy
Session: Poster session 03